在Ib期研究中，ASC30皮下注射剂总体耐受性良好，安全性良好。未报告严重不良事件(SAE)，且未观 察到3级或以上不良事件。大多数胃肠道相关不良事件(AE)为轻度(1级)。包括丙氨酸氨基转移酶 (ALT)、天冬氨酸氨基转移酶(AST)及总胆红素(TBL)在内的肝酶指标未升高。实验室检查、生命体徵、 ECGs(心电图，包括按心率校正的QT间期(QTc))及体格检查均未见异常。大部分的ASC30注射部位反应 均为轻度。未发生3级或以上注射部位反应。 由歌礼自主研发的ASC30是首款也是唯一一款既可每日一次口服也可每月一次或更低频率皮下注射的用 于治疗肥胖症的试验阶段小分子GLP-1R激动剂。 在评估的三种制剂中，其中一种制剂在接受单次皮下注射的肥胖症患者中显示出36天的半衰期，支持每 月一次或更低频率给药。此外，该制剂是一种皮下注射的无菌溶液，在中性pH值附近保持稳定，为与 其他药物或候选药物开发复方制剂及联合给药方案提供可能性。该小分子ASC30皮下注射制剂正在推进 至进一步的临床试验，旨在评估100毫克以上剂量的临床疗效。 另两种制剂与上述制剂的理化性质不同，在肥胖症患者中也显示出了超长效的潜力。 智通财经 ...

这些成就彰显了集团强大的研发能力，以及其长期以来致力于发现和开发具有全球竞争力的差异化管线 产品的决心。 公告称，亏损扩大主要由于肥胖症及其他代谢性疾病的研发开支增加。集团拥有充足的资金以支持其未 来五年的创新研发。 于报告期间及直至本公告日期，集团已就其代谢性疾病管线取得重大进展：(i)每日一次服用ASC30口服 片用于治疗肥胖症：在用于治疗肥胖症患者方面，显示出有望成为同类最佳特性，在治疗28天后，体重 相对基线平均下降最多达6.3%;(ii)每月一次或更低频率的皮下注射ASC30用于治疗肥胖症：作为针对已 验证靶点的小分子GLP-1R偏向激动剂，在用于治疗肥胖症患者方面显示出有望成为同类首创的特性。 其期中数据预计将于2025年3月底公布;及(iii)每月一次或更低频率的皮下注射ASC47用于治疗肥胖症(减 重不减肌)：作为针对新型靶点的脂肪靶向的小分子甲状腺激素受体β(THRβ)激动剂，显示出有望成为 同类首创的特性，有望实现减重不减肌地治疗肥胖症。ASC47在肥胖症患者体内显示出了长达40天的半 衰期。 歌礼制药-B(01672)发布年度业绩 股东应占亏损3.01 亿元 同比扩大107.95% 智通 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of RMB 1,283,000, a significant decrease of 97.7% compared to RMB 56,596,000 for the previous year[3]. - The basic and diluted loss per share increased to RMB 30.05 from RMB 13.47 in the previous year[3]. - The net loss for the year rose to RMB 300.9 million, up from RMB 144.7 million in the previous year, primarily due to increased R&D expenditures related to obesity and other metabolic diseases[6]. - The total revenue decreased from approximately RMB 566 million for the year ended December 31, 2023, to RMB 1.3 million for the year ended December 31, 2024, primarily due to strategic adjustments in response to the easing of the COVID-19 pandemic[32]. - The company's gross profit for the same period was RMB 735,000, down from RMB 25,990,000 in 2023, indicating a decline of about 97.17%[79]. - The company incurred an operating loss of RMB 295,419,000 in 2024, compared to a loss of RMB 124,296,000 in 2023, marking an increase in losses of about 138.56%[79]. - The company reported a basic loss per share of RMB 0.30 for 2024, compared to RMB 0.14 for 2023, based on a weighted average of 1,001,588,704 shares issued[109]. Research and Development - The company's research and development expenses increased by 39.5% from approximately RMB 216.8 million in the previous year to approximately RMB 302.4 million for the current year[6]. - The company emphasizes its commitment to developing a differentiated pipeline of globally competitive products in the metabolic disease sector[5]. - ASC30, a small molecule GLP-1R agonist, shows strong competitive potential for obesity treatment with unique properties allowing both subcutaneous and oral administration[12]. - The company is developing ASC30 and ASC47 for obesity treatment, with ASC30 showing potential best-in-class characteristics and ASC47 targeting a novel mechanism for weight loss without muscle loss[5][7]. - The company has established a comprehensive pipeline for metabolic diseases with key clinical stage assets and plans to announce results from various clinical studies in 2025[30]. - The company plans to announce interim data for ASC30's monthly injection formulation by the end of March 2025[5]. - The company plans to announce topline results from the ASC30 Phase Ib study in the U.S. by 2025[15]. Clinical Trials and Product Development - The company achieved promising interim results for ASC30, showing an average weight reduction of up to 6.3% relative to baseline after 28 days of treatment in the second cohort of a clinical trial[5][11]. - The Phase Ib clinical study for monthly or less frequent subcutaneous ASC30 injections in obesity patients has made significant progress, involving 76 patients across 8 cohorts[14]. - ASC47, a fat-targeting obesity treatment, has shown positive topline results in an Ib study in Australia, with a half-life of up to 40 days supporting monthly dosing[16]. - ASC47 demonstrated an average weight loss of 1.7% by day 50 after a single 90 mg injection, with good tolerability and no serious adverse events reported[16]. - The company has obtained exclusive rights for ASC40 in the Greater China region, which targets fatty acid synthase for acne treatment[8]. - The company plans to complete Phase III clinical studies for ASC40 targeting moderate to severe acne by 2025 and seek commercial partnerships[26]. Financial Position and Cash Flow - The cash and cash equivalents as of December 31, 2024, were approximately RMB 1,980.8 million, down from RMB 2,299.4 million the previous year, which is expected to support R&D activities until 2029[6]. - The net cash used in operating activities was approximately RMB 341.6 million, primarily due to an operating loss of about RMB 355.4 million before changes in working capital[61]. - The net cash generated from investing activities for the year ended December 31, 2024, was approximately RMB 978.9 million, mainly due to a decrease in time deposits of about RMB 866.0 million[62]. - The net cash used in financing activities for the year ended December 31, 2024, was approximately RMB 103.5 million, primarily attributed to the repurchase of shares at a total cost of about RMB 98.5 million[63]. - Cash and cash equivalents, along with time deposits, decreased from approximately RMB 2.27 billion as of December 31, 2023, to approximately RMB 1.94 billion as of December 31, 2024[55]. Corporate Governance and Strategic Decisions - The board does not recommend any dividend payment for the year ending December 31, 2024, consistent with 2023[120]. - The company has decided to terminate the ASC22 project for chronic hepatitis B and the ASC10 project for RSV based on strategic evaluations[19][20]. - The company is actively seeking suitable opportunities for licensing its clinical assets while developing its metabolic disease pipeline[29]. - The company maintains high standards of corporate governance to protect shareholder interests and enhance corporate value[130]. - The audit committee, consisting of three independent non-executive directors, reviewed the annual performance for the year ending December 31, 2024, and recommended approval to the board[135].

Investment Rating - The report maintains a "Buy" rating for the company [4][3]. Core Insights - ASC47, in combination with semaglutide, shows superior weight loss effects in preclinical studies compared to semaglutide alone, with weight reductions of 36.2% and 35.9% for the 3 mg/kg and 9 mg/kg groups respectively [1]. - The company is actively advancing clinical trials for ASC47 in Australia, with a Phase I single ascending dose study showing good tolerability and a half-life of 21 days [2]. - The company is also progressing multiple obesity-related drug candidates, including ASC30, which is undergoing Phase I trials in the US [8]. Financial Forecasts and Valuation - The company has adjusted its net profit forecasts for 2024 and 2025 to -261 million and -313 million CNY respectively, improving from previous estimates of -284 million and -340 million CNY [3]. - The net profit for 2026 is projected at -322 million CNY, reflecting effective cost control measures [3]. Market Data - The total market capitalization of the company is approximately 28.15 billion HKD, with a total share capital of 1.013 billion shares [19]. - The stock has experienced a 1-year high of 2.93 HKD and a low of 0.76 HKD [19]. Earnings Performance - The company reported a revenue of 54 million CNY in 2022, with a projected revenue of 0 CNY for 2024 and beyond [11]. - The earnings per share (EPS) is forecasted to be -0.26 CNY in 2024, worsening to -0.32 CNY by 2026 [11]. Cash Flow Analysis - The operating cash flow is expected to decline from -142 million CNY in 2022 to -292 million CNY by 2026 [21]. - The cash and cash equivalents are projected to decrease from 404 million CNY in 2022 to 98 million CNY by 2026 [21].

证 券 研 究 报 告 | --- | --- | --- | |---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 即时点评 | | 减重不减肌药研发 ...

Financial Performance - Total revenue for the six months ended June 30, 2024, was zero, a decrease of 100% from RMB 46.5 million in the same period of 2023, primarily due to reduced market demand for Ritonavir products following effective control of COVID-19 in mainland China [3]. - The total revenue decreased by 59.7% to approximately RMB 49.0 million for the six months ended June 30, 2024, from approximately RMB 121.5 million in the same period of 2023 [5]. - Total revenue for the period was RMB 49,004,000, down from RMB 75,041,000 in the previous year, indicating a decline of about 34.7% [86]. - The company reported a total comprehensive loss of RMB 121,630,000 for the period, compared to a total comprehensive income of RMB 37,253,000 in the previous year [88]. - The company reported a loss attributable to ordinary equity shareholders of RMB 130,318,000 for the six months ended June 30, 2024, compared to a loss of RMB 16,559,000 for the same period in 2023 [111]. Research and Development - Research and development expenses increased by 43.5% to approximately RMB 132.4 million for the six months ended June 30, 2024, compared to RMB 92.3 million for the same period in 2023 [5]. - The company announced positive interim results from the Phase II clinical trial of ASC41 for treating NASH patients confirmed by liver biopsy [5]. - ASC40's Phase IIb FASCINATE-2 clinical trial for treating NASH also reported positive topline results, indicating progress in metabolic disease treatment [5]. - The company has made significant advancements in internal drug discovery for metabolic diseases during the reporting period [5]. - The company is focusing on ten key clinical stage assets targeting viral diseases, metabolic diseases, and tumors [25]. Cash and Liquidity - Cash and cash equivalents, along with other liquid assets, amounted to approximately RMB 2,117.2 million as of June 30, 2024, compared to RMB 2,516.4 million as of June 30, 2023, expected to support R&D activities until 2028 [5]. - As of June 30, 2024, the company had cash and cash equivalents of approximately RMB 2,117.2 million, sufficient to support R&D activities until 2028 [26]. - The company's cash and cash equivalents stood at RMB 342,994,000 as of June 30, 2024, compared to RMB 330,117,000 at the end of 2023, showing a slight increase of about 3.6% [89]. Clinical Trials and Product Development - ASC22 for chronic hepatitis B has shown a significant HBsAg decline with 21.1% (4 out of 19) of patients achieving HBsAg clearance after 24 weeks of treatment [12]. - ASC10, an oral prodrug for RSV, has demonstrated an EC50 of 0.51 to 0.6 µM against two clinical strains in vitro, indicating strong efficacy [13]. - ASC40, an oral small molecule targeting FASN for NASH, has received fast track designation from the US FDA [9]. - The Phase III trial for ASC40 in rGBM has completed patient enrollment, targeting approximately 180 patients for progression-free survival analysis [18]. - The company plans to submit Phase II data for ASC40 in 2024 and discuss registration trials with regulatory authorities [16]. Shareholder and Corporate Governance - The company’s chairman and CEO positions are held by the same individual, which the board believes enhances efficiency [65]. - The company confirmed compliance with corporate governance codes during the reporting period [65]. - The company did not recommend the payment of an interim dividend for the six months ending June 30, 2024 [79]. - The independent auditor, KPMG, reviewed the interim financial information and found it compliant with applicable accounting standards [78]. Employee and Management Costs - The total employee cost for the six months ended June 30, 2024, was approximately RMB 76.8 million, an increase from RMB 55.3 million for the same period in 2023, primarily due to payments made to R&D personnel [61]. - Total remuneration for key management personnel for the six months ended June 30, 2024, was RMB 44,544,000, significantly up from RMB 14,842,000 in the same period last year [130]. Legal and Regulatory Matters - The company has ongoing litigation with Viking Therapeutics regarding candidate drugs ASC41 and ASC43F, with no provisions made as of June 30, 2024 [128]. - The company incurred litigation expenses of RMB 20,459,000 for the six months ended June 30, 2024, compared to RMB 6,013,000 for the same period in 2023 [108]. Future Outlook and Strategy - The company plans to enhance its digital marketing strategies, aiming for a 20% increase in online engagement by the end of 2024 [135]. - The company is expanding its market presence in the Greater China region, targeting a market share increase of CC% by the end of 2024 [133]. - The company has established partnerships with leading research institutions to accelerate the development of its pipeline products [134].

证 券 研 究 报 告 请务必阅读免责条款 | --- | --- | --- | |---------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Data and Key Metrics - The company's cash reserves as of June 30, 2024, exceeded RMB 2.1 billion, ensuring healthy operations and development for the next five years [1][2] - The company reported a loss of RMB 130 million in the first half of 2024, primarily due to increased R&D investments [1][2] - R&D personnel now account for 69% of the company's total workforce, reflecting a significant increase in R&D focus and efficiency [1][2] Business Line Data and Key Metrics - The company has focused on global BIC (Best-in-Class) and FIC (First-in-Class) pipeline development, particularly in metabolic diseases and oncology [1][2] - Key pipeline highlights include AAC40, which has successfully initiated Phase III trials, and AAC41, which showed promising Phase II results with 93.3% of patients achieving a 30% reduction in liver fat content [1][2] - The company has accelerated the development of global FIC and BIC candidates for metabolic diseases, with plans to continue this focus in the second half of 2024 [1][2] Market Data and Key Metrics - The company has engaged in extensive business development activities, including participation in major industry conferences such as the JP Morgan Healthcare Conference and the BioInnovation Biotechnology Innovation Organization's global PG conference [1][2] - A top-ten global chemical company expressed interest in the company's pipeline, selecting only 70 out of 1,000 biotech companies for meetings, with the company being one of the selected [1][2] Company Strategy and Industry Competition - The company's strategy is centered on global BIC and FIC pipeline development, avoiding "Me Too" drugs and focusing on top-tier competitive targets [1][2] - The company has increased its patent filings, with four new drug invention patents granted and 51 new applications filed in the first half of 2024, strengthening its competitive position [1][2] - The company plans to continue accelerating the development of global FIC and BIC candidates, particularly in metabolic diseases, to maintain its competitive edge [1][2] Management Commentary on Operating Environment and Future Outlook - Management emphasized the importance of healthy survival in a challenging industry environment, focusing on global BIC and FIC pipeline development and business development activities [1][2] - The company expects to complete key clinical milestones in the second half of 2024, including Phase III enrollment for AAC40 and Phase II completion for AAC41, with top-line data expected in the first half of 2025 [1][2] - Management expressed confidence in the company's cash reserves and R&D capabilities, aiming to maximize the value of its core pipelines before engaging in further business development activities [1][2] Other Important Information - The company has initiated a stock repurchase program, having already repurchased RMB 133 million worth of shares, with plans to continue repurchasing if cash reserves allow [1][2] - The company is exploring the potential of its AAC61 small molecule PD-L1 oral inhibitor, seeking potential partners following promising Phase I results [1][2] Summary of Q&A Session Question: What were the main projects driving the increase in R&D expenses in the first half of 2024? - The increase in R&D expenses was primarily driven by Phase III trials for AAC40, Phase II trials for AAC41, and the acceleration of global FIC and BIC candidate development for metabolic diseases [1][2] Question: When will the efficacy data for AAC40's Phase III trials be available? - Efficacy data for AAC40's Phase III trials is expected to be available in the first half of 2025, with safety follow-up data not impacting the efficacy data readout [1][2] Question: Is the company still working on the AS110 monkeypox project? - The company is conducting further internal evaluations of the AS110 monkeypox project, given the recent rise in monkeypox cases [1][2] Question: How does the company view the competition between its two NASH drugs and weight-loss drugs? - The company's NASH drugs (AAC40 and AAC41) are oral medications targeting liver fat reduction, while weight-loss drugs like GLP-1 are injectable and focus on weight management, indicating different market segments [1][2] Question: Will the company continue its stock repurchase program? - The company will prioritize R&D investments but may continue stock repurchases if cash reserves allow, with a focus on maintaining healthy operations and development [1][2] Question: When will the company form a commercialization team? - The company will consider forming a commercialization team once its pipelines receive regulatory approval, with a focus on global markets rather than domestic sales [1][2] Question: What are the company's future early-stage R&D pipeline plans? - The company's early-stage R&D pipeline will continue to focus on metabolic diseases, building on its current pipeline of AAC40 and AAC41 [1][2]

Financial Performance - For the six months ended June 30, 2024, the company reported no revenue, a decrease of 100% compared to RMB 46,506 thousand for the same period in 2023[2]. - The net loss for the period increased by 687.0% to approximately RMB 130,318 thousand for the six months ended June 30, 2024, compared to RMB 16,559 thousand for the same period in 2023[4]. - Basic and diluted loss per share increased by 743.4% to RMB (12.82) for the six months ended June 30, 2024, compared to RMB (1.52) for the same period in 2023[2]. - Other income and gains decreased by 34.7% to approximately RMB 49,004 thousand for the six months ended June 30, 2024, compared to RMB 75,041 thousand for the same period in 2023[2]. - The group reported a total loss of RMB 130.3 million, compared to a loss of RMB 16.6 million for the same period in 2023[54]. - The group’s basic and diluted loss per share for the six months ended June 30, 2024, was RMB (12.82) cents, compared to RMB (1.52) cents in the previous year[54]. Research and Development - The company's R&D expenses increased by 43.5% to approximately RMB 132,382 thousand for the six months ended June 30, 2024, compared to RMB 92,258 thousand for the same period in 2023[4]. - The company is focused on addressing unmet medical needs in viral diseases, metabolic diseases, and oncology[3]. - The company has made significant progress in internal drug discovery for metabolic diseases[5]. - ASC40, an oral small molecule for NASH, has received fast track designation from the FDA in the United States[7]. - The company aims to accelerate the development of global best-in-class candidates for metabolic diseases and enhance its global competitiveness[22]. - The company is exploring various licensing opportunities for its clinical and preclinical assets[22]. - The company plans to establish strategic decisions for ASC22's functional cure for HIV in 2024[13]. - The company plans to establish a strategic decision for ASC10 and ASC11 regarding COVID-19 treatment in 2024[14]. - The company is actively engaged in the development of therapies for recurrent glioblastoma (rGBM), showcasing its commitment to addressing critical health issues[87]. Clinical Trials and Drug Development - The company announced positive interim results for the Phase II clinical trial of ASC41 for treating NASH patients[5]. - ASC22 for chronic hepatitis B achieved a significant HBsAg clearance rate of 21.1% (4 out of 19 patients) after 24 weeks of treatment[10]. - ASC10, an oral prodrug, demonstrated an EC50 of 0.51 to 0.6 µM against RSV in vitro, indicating strong antiviral activity[11]. - The company has received FDA and NMPA approvals to initiate Phase IIa clinical trials for ASC10 targeting RSV infections[11]. - The ASC40 trial for NASH is expected to submit Phase IIb data to the FDA in 2024 and discuss registration trials with the National Medical Products Administration[14]. - The ASC41 trial is set to complete patient enrollment for its Phase II clinical study in 2024[15]. - The ASC40 trial for rGBM has completed patient enrollment, with approximately 180 patients participating in a study assessing progression-free survival and overall survival[16]. - The ASC61 trial for advanced solid tumors has completed patient enrollment in its Phase I clinical trial[17]. - The ASC40 treatment group in the NASH trial had a statistically significant reduction in ALT and AST levels, with reductions of 37.8% and 41.5% respectively after 12 weeks[15]. - The ASC40 trial for rGBM will conduct a mid-term analysis after observing 93 progression-free survival events[16]. Financial Position and Cash Flow - The company had cash and cash equivalents of approximately RMB 2,117.2 million as of June 30, 2024, down from RMB 2,516.4 million as of June 30, 2023[4]. - As of June 30, 2024, the company had no borrowings or outstanding debts, including mortgages, bonds, or bank overdrafts[49]. - The net cash flow used in operating activities was approximately RMB 203.4 million, primarily due to an operating loss of about RMB 149.1 million before changes in working capital[45]. - The net cash flow from investing activities for the same period was approximately RMB 261.6 million, mainly due to the redemption of fixed deposits maturing in over three months amounting to about RMB 243.0 million[46]. - The net cash flow used in financing activities was approximately RMB 45.5 million, primarily related to share repurchases during the reporting period[47]. - The current ratio increased from 16.6 as of December 31, 2023, to 24.4 as of June 30, 2024, while the quick ratio rose from 16.5 to 24.3, primarily due to a decrease in current liabilities[50]. Employee and Corporate Governance - As of June 30, 2024, the group had a total of 219 employees, with 217 located in China, and over 79.5% holding a bachelor's degree or higher[52]. - The total employee cost for the six months ended June 30, 2024, was approximately RMB 76.8 million, an increase from RMB 55.3 million for the same period in 2023, primarily due to R&D personnel compensation[52]. - The company continues to recruit employees through various channels, including recruitment websites and job fairs, and provides training for new hires[52]. - The company maintains high standards of corporate governance and has adopted a code of conduct for securities trading, with all directors confirming compliance during the reporting period[77][78]. Market and Strategic Outlook - The global RSV drug market is projected to grow at a CAGR of 14.9%, reaching $4.2 billion by 2027[11]. - The estimated global population of HIV carriers in 2022 was approximately 39 million, with around 630,000 deaths related to AIDS[13]. - The company is exploring market expansion opportunities, particularly in the United States, to enhance its competitive position[87]. - The strategic emphasis on partnerships and collaborations may lead to potential mergers and acquisitions in the future[87].

Clinical Trials and Development - ASC40 achieved significant efficacy and safety in the Phase II clinical trial for acne, with a mechanism that directly inhibits sebum production and inflammation[3]. - ASC40's Phase III clinical trial for acne is set to complete patient enrollment in 2024, targeting 480 moderate to severe acne patients[20]. - ASC42 demonstrated a 1,780% increase in the biomarker FGF19 and a 91% decrease in C4 levels after 14 days of treatment at a dose of 15 mg once daily[2]. - The company plans to complete patient enrollment for the Phase II clinical trial of ASC41 for NASH in 2024[9]. - The Phase III registration study for ASC40 in rGBM has enrolled 120 patients, with a planned total of 180 patients[13]. - ASC61, a potent oral PD-L1 inhibitor, is currently in a Phase I dose-escalation trial for advanced solid tumors in the U.S.[17]. - The company completed the enrollment of 120 patients in the Phase III clinical trial of ASC40 for rGBM treatment[30]. - The company made a strategic decision to discontinue the ASC42 clinical trial for PBC based on the efficacy and safety data from the Phase II study[39]. - ASC43F, a fixed-dose combination of 5 mg THRβ agonist ASC41 and 15 mg FXR agonist ASC42, demonstrated good safety and tolerability in a Phase I clinical trial with no clinically significant adverse events reported[40]. - ASC22, an immune therapy for functional cure of chronic hepatitis B, is progressing rapidly in clinical development, targeting a significant unmet medical need with approximately 86 million people infected in China[61]. - The company aims to submit Phase II data for ASC40 in the treatment of moderate to severe fibrosis (F2 or F3) NASH patients in the U.S. in 2024[102]. - The company is conducting a Phase II clinical trial for ASC41 in confirmed NASH patients, with interim results expected to be announced on January 2, 2024[103]. - The company is exploring further clinical development opportunities for ASC22 in combination with other drugs for the functional cure of chronic hepatitis B[93]. - The company achieved positive topline results in the 52-week Phase IIb FASCINATE-2 clinical trial for ASC40 in patients with confirmed fibrosis stages 2 or 3 NASH[101]. - The ASC22 trial included 49 patients with baseline HBsAg ≤ 100 IU/mL, treated with 1.0 mg/kg of ASC22 or placebo every two weeks for 24 weeks[195]. - ASC22 combined with vedolizumab showed good tolerability and effectively activated latent HIV reservoirs in a Phase II study with significant increases in CA HIV RNA observed[67]. Financial Performance - The company's total revenue increased by 4.6% from approximately RMB 541 million for the year ended December 31, 2022, to approximately RMB 566 million for the year ended December 31, 2023[27]. - Other income and gains rose by 64.8% from approximately RMB 112 million for the year ended December 31, 2022, to approximately RMB 185 million for the year ended December 31, 2023[27]. - The company's total revenue, including both revenue and other income and gains, increased by 45.2% from approximately RMB 661 million for the year ended December 31, 2022, to approximately RMB 1,241 million for the year ended December 31, 2023[27]. - Gross profit for the year ended December 31, 2023, was approximately RMB 26 million, compared to a gross loss of approximately RMB 25 million for the year ended December 31, 2022[28]. - The company recorded a net loss of approximately RMB 145 million for the year ended December 31, 2023, compared to a net loss of approximately RMB 315 million for the year ended December 31, 2022[26]. - The net loss margin for the year ended December 31, 2023, was (255.7)%, compared to (582.1)% for the year ended December 31, 2022[26]. - The company's administrative expenses rose by 228.5% to approximately RMB 115.6 million for the year ended December 31, 2023, from approximately RMB 35.2 million for the year ended December 31, 2022, mainly due to increased consulting fees and employee-related costs[119]. - The company's annual loss decreased from RMB 314.8 million for the year ended December 31, 2022, to RMB 144.7 million for the year ended December 31, 2023, primarily due to increased product sales revenue and improved inventory management[187]. - The company reported a significant reduction in other expenses from approximately RMB 59.8 million for the year ended December 31, 2022, to approximately RMB 2.1 million for the year ended December 31, 2023, mainly due to a decrease in impairment of other intangible assets[149]. - The company's financing costs were approximately RMB 0.1 million for the year ended December 31, 2023, down from RMB 0.2 million for the year ended December 31, 2022, due to interest on lease liabilities[150]. Research and Development - The company has established a pipeline of 12 key clinical stage assets focusing on viral diseases, NASH, and tumors[9]. - The company aims to enhance its global competitiveness by accelerating the development of innovative or best-in-class candidates[9]. - The company is focusing on expanding its product pipeline in viral diseases and oncology, with several candidates in various clinical trial phases[190][192]. - The company is developing multiple products targeting NASH and PBC, including ASC40, ASC41, ASC42, and ASC43F, with global rights for most products[190]. - ASC40, a combination of FASN and VEGF, is aimed at treating recurrent glioblastoma in the Greater China region[192]. - ASC61 targets PD-L1 for late-stage solid tumors and is in the global development stage[192]. - The company is advancing the ASC10 and ASC11 programs for COVID-19 and RSV, respectively, with ongoing clinical evaluations[109]. Sustainability and Corporate Strategy - The company has implemented several initiatives to reduce its carbon footprint, reflecting its commitment to sustainability[24]. - The company is seeking opportunities to license multiple clinical assets[8]. - The company is exploring various licensing opportunities for preclinical and clinical stage assets to optimize resource strategy[78]. - The company aims to leverage its innovative therapies to address unmet medical needs in chronic hepatitis B and cancer[195]. - The company plans to complete a comprehensive data analysis of the ASC22 combined ART Phase II study in 2024 to inform strategic decisions[84]. - The company has obtained exclusive rights for ASC40 in the Greater China region from Sagimet Biosciences[56]. - The company has received six IND approvals from the FDA and/or the National Medical Products Administration, supporting four candidates in ongoing Phase II or III clinical trials[108]. Inventory and Receivables Management - The company's inventory decreased from approximately RMB 20.5 million as of December 31, 2022, to approximately RMB 6.1 million as of December 31, 2023, primarily due to a decline in sales of COVID-19 products leading to impairment of Ritonavir products[126]. - Trade receivables decreased significantly from approximately RMB 23.9 million as of December 31, 2022, to approximately RMB 5.4 million as of December 31, 2023[128]. - The company's deductible VAT input tax increased by 164.4% from approximately RMB 5.4 million as of December 31, 2022, to approximately RMB 14.3 million as of December 31, 2023, mainly due to a decrease in VAT refunds[158]. - Trade receivables decreased from approximately RMB 23.9 million as of December 31, 2022, to approximately RMB 5.4 million as of December 31, 2023, primarily due to the cessation of promotional services for Palosim in China[162]. - The company's prepaid expenses decreased by 49.2% from approximately RMB 8.1 million as of December 31, 2022, to approximately RMB 4.1 million as of December 31, 2023, due to reduced R&D-related prepayments[164].